{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:39:11Z","timestamp":1781710751191,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00117-025-01472-8","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T17:08:44Z","timestamp":1749834524000},"page":"490-499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Moderne systemische Therapie \u2013 bispezifische Antik\u00f6rper und CAR-T-Zell-Therapie","Modern systemic treatment\u2014bispecific antibodies and CAR-T\u00a0cell therapy"],"prefix":"10.1007","volume":"65","author":[{"given":"Henriette","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Leupolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00fcndgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"1472_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn\u00a0LH, Salles\u00a0G (2021) Diffuse Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 384:842\u2013858. https:\/\/doi.org\/10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"issue":"73","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"2023","author":"RL Siegel","year":"2023","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Wagle\u00a0NS et\u00a0al (2023) Cancer statistics. CA Cancer J Clin 2023(73):17\u201348","journal-title":"CA Cancer J Clin"},{"key":"1472_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier\u00a0B, Lepage\u00a0E, Bri\u00e8re\u00a0J et\u00a0al (2002) CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. N\u00a0Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"1472_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly\u00a0H, Morschhauser\u00a0F, Sehn\u00a0LH et\u00a0al (2022) Polatuzumab Vedotin in Previously Untreated Diffuse Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 386:351\u2013363","journal-title":"N Engl J Med"},{"key":"1472_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke\u00a0FL, Miklos\u00a0DB, Jacobson\u00a0CA et\u00a0al (2022) Axicabtagene Ciloleucel as Second-Line Therapy for Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 386:640\u2013654","journal-title":"N Engl J Med"},{"key":"1472_CR6","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2022-159702","volume":"140","author":"JS Abramson","year":"2022","unstructured":"Abramson\u00a0JS, Solomon\u00a0SR, Arnason\u00a0JE et\u00a0al (2022) Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B\u2011Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase\u00a03 Transform Study. Blood 140:1581\u20131583","journal-title":"Blood"},{"issue":"7","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"17;386","author":"MR Bishop","year":"2022","unstructured":"Bishop\u00a0MR, Dickinson\u00a0M, Purtill\u00a0D et\u00a0al (2022) Second-Line Tisagenlecleucel or Standard Care in Aggressive B\u2011Cell Lymphoma. N\u00a0Engl J Med 17;386(7):629\u2013639 (Feb)","journal-title":"N Engl J Med"},{"key":"1472_CR8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje\u00a0N, Berdeja\u00a0J, Lin\u00a0Y et\u00a0al (2019) Anti-BCMA CAR T\u2011Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N\u00a0Engl J Med 380:1726\u20131737","journal-title":"N Engl J Med"},{"issue":"19","key":"1472_CR9","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu\u00a0SS, Jacobsen\u00a0CA, Ghobadi\u00a0A et\u00a0al (2023) Blood 141(19):2307\u20132315","journal-title":"Blood"},{"key":"1472_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin\u00a0JR, Oluwole\u00a0OO, Kersten\u00a0MJ et\u00a0al (2023) Survival with Axicabtagene Ciloleucel in Large B\u2011Cell Lymphoma. N\u00a0Engl J Med 389:148\u2013157","journal-title":"N Engl J Med"},{"key":"1472_CR11","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil\u00a0LJ, Jain\u00a0MD, Feng\u00a0L et\u00a0al (2020) Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B\u2011Cell Lymphoma:Results From the US Lymphoma CAR T Consortium. J\u00a0Clin Oncol 38:3119\u20133128","journal-title":"J Clin Oncol"},{"key":"1472_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejca.2022.08.019","volume":"175","author":"S Vic","year":"2022","unstructured":"Vic\u00a0S, Lemoine\u00a0J, Armand\u00a0P et\u00a0al (2022) Transplant-ineligible but chimeric antigen receptor T\u2011cells eligible: a\u00a0real and relevant population. Eur J Cancer 175:246\u2013253 (Nov)","journal-title":"Eur J Cancer"},{"key":"1472_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s44228-022-00004-8","volume":"4","author":"R Ellard","year":"2022","unstructured":"Ellard\u00a0R, Kenyon\u00a0M, Hutt\u00a0D et\u00a0al (2022) The EBMT Immune Effector Cell Nursing Guidelines on CAR\u2011T Therapy: A\u00a0Framework for Patient Care and Managing Common Toxicities. Clin Hematol Int 4:75\u201388","journal-title":"Clin Hematol Int"},{"key":"1472_CR14","doi-asserted-by":"publisher","first-page":"7566","DOI":"10.1200\/JCO.2021.39.15_suppl.7566","volume":"39","author":"C Oliai","year":"2021","unstructured":"Oliai\u00a0C, Crosetti\u00a0A, De Vos\u00a0S et\u00a0al (2021) IL\u20111 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome. JCO 39:7566","journal-title":"JCO"},{"key":"1472_CR15","unstructured":"(2023) FDA Investigating Serious Risk of T\u2011cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T\u00a0cell Immunotherapies. https:\/\/www.fda.gov\/vaccines-bloodbiologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cellmalignancy-following-bcma-directed-or-cd19-directed-autologous. Zugegriffen: 12. Jan. 2025"},{"issue":"13","key":"1472_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","volume":"3;391","author":"G Kobbe","year":"2024","unstructured":"Kobbe\u00a0G, Br\u00fcggemann\u00a0M, Baermann\u00a0BN et\u00a0al (2024) Aggressive Lymphoma after CD19 CAR T\u2011Cell Therapy. N\u00a0Engl J Med 3;391(13):1217\u20131226 (Oct)","journal-title":"N Engl J Med"},{"key":"1472_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi\u00a0A, Arumov\u00a0A, Schatz\u00a0JH (2024) Bispecific antibodies and CAR-T\u00a0cells: dueling immunotherapies for large B\u2011cell lymphomas. Blood Cancer\u00a0J 14:27","journal-title":"Blood Cancer J"},{"issue":"10","key":"1472_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"M Herrera","year":"2024","unstructured":"Herrera\u00a0M, Pretelli\u00a0G, Desai\u00a0J et\u00a0al (2024) Bispecific antibodies: advancing precision oncology. Trends Cancer 10(10):893\u2013919","journal-title":"Trends Cancer"},{"key":"1472_CR19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian\u00a0H, Stein\u00a0A, G\u00f6kbuget\u00a0N et\u00a0al (2017) Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N\u00a0Engl J Med 376:836\u2013847","journal-title":"N Engl J Med"},{"key":"1472_CR20","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","volume":"3","author":"V Dufner","year":"2019","unstructured":"Dufner\u00a0V, Sayehli\u00a0CM, Chatterjee\u00a0M et\u00a0al (2019) Long-term outcome of patients with relapsed\/refractory B\u2011cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv 3:2491\u20132498","journal-title":"Blood Adv"},{"key":"1472_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi\u00a0L, Vardhana\u00a0SA, Salles\u00a0GA (2023) Bispecific antibodies for the treatment of B\u2011cell lymphoma: promises, unknowns, and opportunities. Blood 141:467\u2013480","journal-title":"Blood"},{"key":"1472_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks\u00a0V, Rossi\u00a0JM, Chou\u00a0J et\u00a0al (2021) CD19 target evasion as a\u00a0mechanism of relapse in large B\u2011cell lymphoma treated with axicabtagene ciloleucel. Blood 138:1081\u20131085","journal-title":"Blood"},{"key":"1472_CR23","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings\u00a0M, Morschhauser\u00a0F, Iacoboni\u00a0G et\u00a0al (2021) Glofitamab, a\u00a0Novel, Bivalent CD20-Targeting T\u2011Cell\u2013Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B\u2011Cell Lymphoma: A\u00a0Phase\u00a0I Trial. JCO 39:1959\u20131970","journal-title":"JCO"},{"key":"1472_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/hon.3163_95","volume":"41","author":"M Dickinson","year":"2023","unstructured":"Dickinson\u00a0M, Carlo-Stella\u00a0C, Morschhauser\u00a0F et\u00a0al (2023) Glofitamab Monotherapy in Patients with Relapsed\/Refractory (r\/R) Large B\u2011Cell Lymphoma (lbcl): Extended Follow-up and Landmark Analyses from a\u00a0Pivotal Phase\u00a0Ii Study. Hematol Oncol 41:144\u2013146","journal-title":"Hematol Oncol"},{"issue":"10466","key":"1472_CR25","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","volume":"404","author":"JS Abramson","year":"2024","unstructured":"Abramson\u00a0JS, Ku\u00a0W, Hertzberg\u00a0M et\u00a0al (2024) Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B\u2011cell lymphoma (STARGLO): a\u00a0global phase\u00a03, randomised, open-label trial. Lancet 404(10466):1940\u20131954","journal-title":"Lancet"},{"key":"1472_CR26","unstructured":"Thieblemont C, Karimi Y, Ghesquieres H et\u00a0al (2024) Extended follow-up beyond 2.5\u00a0years shows long-term efficacy in complete responders following epcoritamab monotherapy in relapsed or refractory large b\u2011cell lymphoma. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/419238\/catherine.thieblemont.extended.follow-up.beyond.2.5.years.shows.long-term.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29171%2Amarker%3D5101%2Afeatured%3D18527. Zugegriffen: 12. Jan. 2025"},{"key":"1472_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/hon.3163_93","volume":"41","author":"M Poon","year":"2023","unstructured":"Poon\u00a0M, Walewski\u00a0J, Kim\u00a0TM et\u00a0al (2023) Odronextamab in Patients with Relapsed\/Refractory Diffuse Large B\u2011Cell Lymphoma (dlbcl): Results from a\u00a0Prespecified Analysis of the Pivotal Phase\u00a0II Study Elm\u20112. Hematol Oncol 41:141\u2013142","journal-title":"Hematol Oncol"},{"key":"1472_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi\u00a0CL, Sha\u00a0F, Alperovich\u00a0A et\u00a0al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer\u00a0J 10:74","journal-title":"Blood Cancer J"},{"issue":"23","key":"1472_CR29","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"10;33","author":"C Casulo","year":"2015","unstructured":"Casulo\u00a0C, Byrtek\u00a0M, Dawson\u00a0KL et\u00a0al (2015) Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J\u00a0Clin Oncol 10;33(23):2516\u20132522 (Aug)","journal-title":"J Clin Oncol"},{"issue":"(17","key":"1472_CR30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2023021567","volume":"143","author":"M Dreyling","year":"2024","unstructured":"Dreyling\u00a0M, Fowler\u00a0NH, Dickinson\u00a0M et\u00a0al (2024) Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood 143((17):1713\u20131725","journal-title":"Blood"},{"key":"1472_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson\u00a0CA, Chavez\u00a0JC, Sehgal\u00a0AR et\u00a0al (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a\u00a0single-arm, multicentre, phase\u00a02\u00a0trial. Lancet Oncol 23:91\u2013103","journal-title":"Lancet Oncol"},{"key":"1472_CR32","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser\u00a0F, Dahiya\u00a0S, Palomba\u00a0ML et\u00a0al (2024) Lisocabtagene maraleucel in follicular lymphoma: the phase\u00a02 TRANSCEND FL study. Nat Med 30:2199\u20132207","journal-title":"Nat Med"},{"issue":"19","key":"1472_CR33","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1200\/JCO.23.02329","volume":"42","author":"LE Budde","year":"2024","unstructured":"Budde\u00a0LE, Assouline\u00a0S, Sehn\u00a0LH et\u00a0al (2024) Durable Responses With Mosunetuzumab in Relapsed\/Refractory Indolent and Aggressive B\u2011Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a\u00a0Phase\u00a0I\/II Study. J\u00a0Clin Oncol 42(19):2250\u20132256","journal-title":"J Clin Oncol"},{"key":"1472_CR34","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Chavez JC, Sehgal AR et\u00a0al (2024) 5\u2011Year Follow-up Analysis from ZUMA-5: A\u00a0Phase\u00a02 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma Abstract 864 ASH. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper194627.html. Zugegriffen: 12. Jan. 2025","DOI":"10.1182\/blood-2024-194627"},{"issue":"4","key":"1472_CR35","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling\u00a0M, Campo\u00a0E, Hermine\u00a0O et\u00a0al (2017) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(4):iv62\u2013iv71. https:\/\/doi.org\/10.1093\/annonc\/mdx223","journal-title":"Ann Oncol"},{"issue":"3","key":"1472_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang\u00a0M, Munoz\u00a0J, Goy\u00a0A et\u00a0al (2023) Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2\u00a0Study. J\u00a0Clin Oncol 41(3):555\u2013567","journal-title":"J Clin Oncol"},{"key":"1472_CR37","unstructured":"https:\/\/www.german-lymphoma-alliance.de\/study-EC701A07-EC73-A639-7E66-A467CBBFB8BE.html (letzter Zugriff am 12. Jan. 2025)"},{"key":"1472_CR38","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio\u00a0R, Amador\u00a0C, Anagnostopoulos\u00a0I et\u00a0al (2022) The 5th\u00a0edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"1472_CR39","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","volume":"39","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf\u00a0O, Zhang\u00a0C, Lu\u00a0T et\u00a0al (2021) Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J\u00a0Clin Oncol 39:4049\u20134060. https:\/\/doi.org\/10.1200\/JCO.21.01181","journal-title":"J Clin Oncol"},{"issue":"6","key":"1472_CR40","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7.","volume":"25","author":"M F\u00fcrstenau","year":"2024","unstructured":"F\u00fcrstenau\u00a0M, Kater\u00a0AP, Robrecht\u00a0S et\u00a0al (2024) First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4\u2011year follow-up from a\u00a0multicentre, open-label, randomised, phase\u00a03\u00a0trial. Lancet Oncol 25(6):744\u2013759. https:\/\/doi.org\/10.1016\/S1470-2045(24)00196-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"1472_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2023022861","volume":"144","author":"RI Lewis","year":"2024","unstructured":"Lewis\u00a0RI, Vom\u00a0SAF, Hallek\u00a0M (2024) Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia. Blood 144(6):601\u2013614","journal-title":"Blood"},{"issue":"9","key":"1472_CR42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41408-022-00721-6","volume":"12","author":"PJ Hampel","year":"2022","unstructured":"Hampel\u00a0PJ, Rabe\u00a0KG, Call\u00a0TG et\u00a0al (2022) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer\u00a0J 12(9):124","journal-title":"Blood Cancer J"},{"issue":"10402","key":"1472_CR43","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi\u00a0T, Maloney\u00a0DG, Kenderian\u00a0SS et\u00a0al (2023) Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a\u00a0multicentre, open-label, single-arm, phase\u00a01\u20132\u00a0study. Lancet 402(10402):641\u2013654 (Aug)","journal-title":"Lancet"},{"key":"1472_CR44","unstructured":"Wierda WG, Dorritie K, Gauthier J et\u00a0al (2024) Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL). https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper200339.html. Zugegriffen: 12. Jan. 2025 (Primary Results from the Open-Label, Phase 1\/2 Transcend CLL 004 Study)"},{"issue":"1","key":"1472_CR45","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1182\/blood-2022-158298","volume":"140","author":"AP Kater","year":"2022","unstructured":"Kater\u00a0AP, Ye\u00a0JC, Sandoval-Sus\u00a0J et\u00a0al (2022) Subcutanous epcoritamab in patients with Richter\u2019s syndrome: early results from phase\u00a01b\/2\u00a0trial (ECPORE CLL-1). Blood 140(1):850\u2013851","journal-title":"Blood"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-025-01472-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-025-01472-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-025-01472-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:29:37Z","timestamp":1750940977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-025-01472-8"}},"subtitle":["Klinischer Ablauf, Wirkmechanismen, Resultate","Clinical management, mechanisms of action, outcomes"],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1007\/s00117-025-01472-8","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"19 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Huber: Vortragshonorare von AbbVie, Janssen-Cilag, BeiGene, Lilly; Advisory Boards: Janssen-Cilag, BeiGene. M.\u00a0Bentz: Vortragshonorare: Roche, Janssen-Cilag, AbbVie, Sanofi-Aventis; Advisory Boards: AbbVie, Gilead, Janssen-Cilag. E.\u00a0Leupolt und L.\u00a0K\u00fcndgen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}